- Home
- / Taysha Gene Therapies
Taysha Gene Therapies
Stock Price
$2.2
2024-09-12
Market Capitalization
$448.8 M
2024-09-12
Revenue
$15.5 M
FY, 2023
Taysha Gene Therapies Summary
Company Summary
- Overview
- Taysha Gene Therapies is a biotechnology company that develops therapies. It offers gene therapies for the treatment of monogenic diseases of the central nervous system (CNS). The company specializes in neurodegenerative diseases, neurodevelopmental disorders, and genetic epilepsies.
- Type
- Public
- Status
- Active
- Founded
- 2020
- HQ
- Dallas, TX, US | view all locations
- Website
- https://tayshagtx.com
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Tracy M. Porter, Chief People Officer
Kamran Alam, Chief Financial Officer
Mishima Gerhart, Chief Regulatory Officer and Head of Quality
Operating MetricsView all
Facility Space, sq. ft.
233
15.3%
FY, 2021
Taysha Gene Therapies Financials
Summary Financials
- Revenue (Q2, 2024)
- $1.1M
- Net income (Q2, 2024)
- ($20.9M)
- Cash (Q2, 2024)
- $172.7M
- EBIT (Q2, 2024)
- ($21.3M)
- Enterprise value
- $313.3M